Ebvallo
1 known investors
EBVALLO is an on-demand allogeneic T-cell immunotherapy for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease. The therapy uses anti-EBV-specific cytotoxic T-cells expanded from third-party donors and matched to patient HLA compatibility.
Investors · 1
Frequently asked questions
- What does Ebvallo do?
- EBVALLO is an on-demand allogeneic T-cell immunotherapy for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease. The therapy uses anti-EBV-specific cytotoxic T-cells expanded from third-party donors and matched to patient HLA compatibility.
- Who are Ebvallo's investors?
- Ebvallo's investors include HEALTHCARE ROYALTY PARTNERS.